Clinical Report: Geographic Atrophy: Fact or Fiction

Overview

Revise to state that GA significantly impacts central vision but does not lead to total blindness.

Background

Geographic atrophy is a severe form of age-related macular degeneration (AMD) that affects millions globally, leading to significant visual impairment. Misunderstandings about GA can hinder timely treatment and worsen patient outcomes. With the recent approval of specific therapies, it is crucial for healthcare providers to address these misconceptions and improve patient education.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Patients often fear total vision loss from AMD, but GA does not lead to complete blindness.
• All forms of AMD are detrimental; both dry and wet AMD can lead to severe vision loss.
• GA typically progresses faster than previously believed, with an average time from diagnosis to central vision loss of 2.5 years.
• Recent FDA approvals for GA treatments, such as pegcetacoplan and avacincaptad pegol, have changed the management landscape.
• Regular monitoring and lifestyle modifications can help preserve vision in patients with GA.
• Many patients with severe visual impairments are not referred to low vision specialists, impacting their quality of life.

Clinical Implications

Healthcare providers should prioritize educating patients about the nature of GA and the importance of early intervention. Regular assessments and referrals to specialists for low vision aids can enhance patient outcomes and quality of life.

Conclusion

Geographic atrophy is a serious condition that requires accurate understanding and management. With emerging treatments and increased awareness, patients can maintain better visual function and independence.

References

1. Jessica Haynes, OD, FAAO, FORS, Dipl ABO, Optometric Management, 2025 -- Geographic Atrophy: Early Detection and Patient Awareness Matters
2. Jessica Haynes, OD, FAAO, FORS, Dipl ABO, Optometric Management, 2025 -- Identifying Geographic Atrophy Biomarkers
3. AAO Preferred Practice Pattern - University of Miami, 2025 -- AAO Preferred Practice Pattern
4. ScienceDirect, 2023 -- Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY)
5. Optometric Management — Identifying Geographic Atrophy Biomarkers
6. optometric management — Detecting Diagnostic and Prognostic Biomarkers of Geographic Atrophy
7. AAO Preferred Practice Pattern - University of Miami
8. Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials - ScienceDirect
9. Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial - PubMed